A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance

Guerreiro, Ana S; Fattet, Sarah; Kulesza, Dorota W; Atamer, Abdullah; Elsing, Alexandra N; Shalaby, Tarek; Jackson, Shaun P; Schoenwaelder, Simone M; Grotzer, Michael A; Delattre, Olivier; Arcaro, Alexandre (2011). A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. Molecular cancer research, 9(7), pp. 925-35. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1541-7786.MCR-10-0200

Full text not available from this repository. (Request a copy)

Medulloblastoma is the most common malignant brain tumor in children and is associated with a poor outcome. We were interested in gaining further insight into the potential of targeting the human kinome as a novel approach to sensitize medulloblastoma to chemotherapeutic agents. A library of small interfering RNA (siRNA) was used to downregulate the known human protein and lipid kinases in medulloblastoma cell lines. The analysis of cell proliferation, in the presence or absence of a low dose of cisplatin after siRNA transfection, identified new protein and lipid kinases involved in medulloblastoma chemoresistance. PLK1 (polo-like kinase 1) was identified as a kinase involved in proliferation in medulloblastoma cell lines. Moreover, a set of 6 genes comprising ATR, LYK5, MPP2, PIK3CG, PIK4CA, and WNK4 were identified as contributing to both cell proliferation and resistance to cisplatin treatment in medulloblastoma cells. An analysis of the expression of the 6 target genes in primary medulloblastoma tumor samples and cell lines revealed overexpression of LYK5 and PIK3CG. The results of the siRNA screen were validated by target inhibition with specific pharmacological inhibitors. A pharmacological inhibitor of p110γ (encoded by PIK3CG) impaired cell proliferation in medulloblastoma cell lines and sensitized the cells to cisplatin treatment. Together, our data show that the p110γ phosphoinositide 3-kinase isoform is a novel target for combinatorial therapies in medulloblastoma.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine

UniBE Contributor:

Arcaro, Alexandre

ISSN:

1541-7786

Publisher:

American Association for Cancer Research AACR

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:24

Last Modified:

06 Dec 2013 13:29

Publisher DOI:

10.1158/1541-7786.MCR-10-0200

PubMed ID:

21652733

Web of Science ID:

000292875000011

URI:

https://boris.unibe.ch/id/eprint/8326 (FactScience: 213847)

Actions (login required)

Edit item Edit item
Provide Feedback